Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this highflier among biotech stocks had surged more than fivefold, to around $106 per share.But then came news of Merck's (NYSE: MRK) plans to acquire Cidara for $221.50 per share, or a 109% premium to its prior trading price. As a result of the takeover news, shares surged by over 100% on Nov. 14, the day of the deal announcement. Why is Merck willing to pony up for Cidara? Could other bidders emerge? If this is a done deal, are there any takeaways for investors? Let's explore each question and see how this news could help identify similar such opportunities.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool